Mumbai,
India | 23rd January, 2026 : Novo
Medi Sciences Pvt. Ltd. (Novo Group), a legacy-driven pharmaceutical company
with 80 years of expertise in developing niche biological products such as
vaccines and life-saving critical care solutions, has announced the launch of NEXIPOX
PLUS®, the most recent innovation in Varicella vaccine since decades.
NEXIPOX PLUS® has been developed with a clear focus on addressing the unique
clinical, environmental, and operational needs of Indian patients and
healthcare settings, making Novo Medi Sciences the only company to
proactively upgrade varicella vaccine specifically for India.
Live
attenuated varicella vaccines are inherently thermolabile, making formulation
stability and potency retention critical to ensuring effective immunisation
outcomes. Recognising the challenges posed by real-world Indian conditions,
NEXIPOX PLUS® has been developed with 2X trehalose-based stabiliser system,
representing a significant evolution in formulation that are result oriented.
By replacing conventional stabilisers such as gelatin and mannitol, the
formulation enhances viral stability, preserves potency, and significantly
reduces the risk of allergic reactions and antigen crystallisation-related
issues, supporting more reliable vaccine performance across storage, handling,
and administration.
Clinical
data demonstrates strong immunogenic performance of NEXIPOX PLUS®. Speaking on
the same and the launch, Forum Bhagat, Managing Director, Novo Medi Sciences
(Novo Group), said, “NEXIPOX PLUS ® reflects our commitment to advancing
vaccine science beyond incremental changes. The results of the clinical trial
on Indian Patients has shown high seroconversion rates of 98% following
a two-dose schedule, supported by a 35.4-fold geometric mean rise in
antibody titres, indicating a robust immune response and effective
protection against varicella virus.”
NEXIPOX
PLUS® has demonstrated a favourable safety profile in clinical studies with no
serious adverse events causally linked to the vaccine in comparative
clinical trials. The removal of gelatin from the formulation further supports
improved tolerability.
Commenting
on the clinical relevance, renowned pediatrician, Dr Nitin K. Shah,
Consultant Pediatrician and Pediatric Hemato-Oncologist, Mumbai, said,
“While stability and safety are already well established in varicella
vaccination, the real clinical advancement with NEXIPOX PLUS® lies in its
enhanced immunogenicity. By building on a stable and reliable formulation, the
use of 2× trehalose alongside advances in formulation and manufacturing has
translated into stronger and more consistent immune responses, offering
tangible benefits in routine immunisation and reinforcing clinician
confidence.”
The
prevalence of chickenpox remains high in India, and the introduction of NEXIPOX
PLUS® aligns with broader public health goals of reducing disease burden and
improving vaccination compliance. Designed with affordability, scalability, and
operational reliability in mind, the vaccine supports adoption in private
practice and strengthens the overall immunisation ecosystem.
NEXIPOX
PLUS® is approved by the Drugs Controller General of India (DCGI) for
use from 12 months of age. Backed by patented technology across 156
countries, the product reflects strong global regulatory readiness, with
international expansion strategies being evaluated based on public health needs
and sustainable supply considerations.
With
NEXIPOX PLUS®, Novo Medi Sciences (Novo Group) reinforces its focus on formulation-led
vaccine innovation, delivering advancements that enhance stability, safety,
and clinical confidence in modern immunisation practices.
About
Novo Medi Sciences (Novo Group):
Novo
Medi Sciences Pvt. Ltd. (Novo Group) is a legacy-driven pharmaceutical company
with over 80 years of expertise in developing niche biological products such as
vaccines and life-saving critical care products. Established in 1946 by the
visionary Shri Ramesh C. Bhagat, who introduced several life-saving vaccines
for the first time in India, Novo Medi Sciences (Novo Group) has consistently
prioritised innovation and accessibility in healthcare. Under the stewardship
of the third-generation leadership, Forum Vipul Bhagat and Karan Vipul Bhagat —
the company continues to pioneer in immunisation and critical care, with a
portfolio that includes the World's only thermostable chickenpox vaccine,
NEXIPOX PLUS®️. Novo Medi Sciences (Novo Group) remains at the forefront of
public health advancements, with 40 first-to-India molecules and a robust
pipeline of vaccines under clinical trials. The company expects to launch at
least two vaccines each year starting from as early as 2026 and have a complete
portfolio of niche vaccines within the next 4 years for all age groups covering
diseases such as Pneumonia, Meningitis, Cervical Cancer, Herpes Shingles, and
many more. While being dominant in the Indian vaccine segment, the company is
committed to ensuring global healthcare access, with its medicines
internationally available in over 45 countries while maintaining the highest
standards of quality and efficacy since 1946.